Enveric Biosciences Stock Revenue Per Share
ENVB Stock | USD 0.40 0.01 2.56% |
Enveric Biosciences fundamentals help investors to digest information that contributes to Enveric Biosciences' financial success or failures. It also enables traders to predict the movement of Enveric Stock. The fundamental analysis module provides a way to measure Enveric Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enveric Biosciences stock.
Enveric |
Enveric Biosciences Company Revenue Per Share Analysis
Enveric Biosciences' Revenue per Share is a ratio of total revenue earned per one share of common stock over a single fiscal year. It is calculated by dividing sales revenue earned over 12 months by the average number of outstanding shares. Revenue used in the calculation of this ratio is typically recorded when cash or cash equivalents are exchanged for services or goods.
Revenue per share does not take into account any of company expenses and is helpful only when comparing relative sale figures within a given industry.
Competition |
Based on the latest financial disclosure, Enveric Biosciences has a Revenue Per Share of 0.0 times. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
All Next | Launch Module |
Enveric Fundamentals
Return On Equity | -2.06 | ||||
Return On Asset | -0.8 | ||||
Current Valuation | (2.97 M) | ||||
Shares Outstanding | 10.17 M | ||||
Shares Owned By Insiders | 6.92 % | ||||
Shares Owned By Institutions | 7.05 % | ||||
Number Of Shares Shorted | 157.21 K | ||||
Price To Book | 1.04 X | ||||
Price To Sales | 0.08 X | ||||
Gross Profit | 8.15 M | ||||
EBITDA | (16.85 M) | ||||
Net Income | (17.29 M) | ||||
Cash And Equivalents | 18.01 M | ||||
Cash Per Share | 11.44 X | ||||
Total Debt | 2.34 M | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 8.33 X | ||||
Book Value Per Share | 0.71 X | ||||
Cash Flow From Operations | (14.09 M) | ||||
Short Ratio | 0.31 X | ||||
Earnings Per Share | (2.42) X | ||||
Target Price | 8.32 | ||||
Beta | 0.47 | ||||
Market Capitalization | 4.1 M | ||||
Total Asset | 4.3 M | ||||
Retained Earnings | (96.5 M) | ||||
Working Capital | 1.24 M | ||||
Net Asset | 4.3 M |
About Enveric Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enveric Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enveric Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enveric Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.S | SentinelOne | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Enveric Biosciences Piotroski F Score and Enveric Biosciences Altman Z Score analysis. For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. If investors know Enveric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enveric Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enveric Biosciences is measured differently than its book value, which is the value of Enveric that is recorded on the company's balance sheet. Investors also form their own opinion of Enveric Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Enveric Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enveric Biosciences' market value can be influenced by many factors that don't directly affect Enveric Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enveric Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enveric Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enveric Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.